CN116143859A - Preparation method of 5α-pregna-3,20-dione - Google Patents
Preparation method of 5α-pregna-3,20-dione Download PDFInfo
- Publication number
- CN116143859A CN116143859A CN202211577135.5A CN202211577135A CN116143859A CN 116143859 A CN116143859 A CN 116143859A CN 202211577135 A CN202211577135 A CN 202211577135A CN 116143859 A CN116143859 A CN 116143859A
- Authority
- CN
- China
- Prior art keywords
- pregna
- dione
- preparation
- hydroxy
- catalytic oxidation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000003197 catalytic effect Effects 0.000 claims abstract description 21
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 20
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims abstract description 14
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims abstract description 13
- 239000003054 catalyst Substances 0.000 claims abstract description 12
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims abstract description 11
- 230000003647 oxidation Effects 0.000 claims abstract description 10
- AKKLAJYCGVIWBS-UHFFFAOYSA-N O=[N].CC1(C)CCCC(C)(C)N1 Chemical compound O=[N].CC1(C)CCCC(C)(C)N1 AKKLAJYCGVIWBS-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000007800 oxidant agent Substances 0.000 claims abstract description 6
- 239000007858 starting material Substances 0.000 claims abstract description 6
- 239000003444 phase transfer catalyst Substances 0.000 claims abstract description 5
- AURFZBICLPNKBZ-FZCSVUEKSA-N 3beta-hydroxy-5alpha-pregnan-20-one Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-FZCSVUEKSA-N 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 16
- 239000003960 organic solvent Substances 0.000 claims description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 8
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 2
- 125000003963 dichloro group Chemical group Cl* 0.000 claims 1
- 150000003949 imides Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 15
- 238000006243 chemical reaction Methods 0.000 abstract description 14
- 239000002994 raw material Substances 0.000 abstract description 4
- 230000001590 oxidative effect Effects 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 2
- 150000002576 ketones Chemical class 0.000 abstract description 2
- 238000007039 two-step reaction Methods 0.000 abstract description 2
- 150000001412 amines Chemical class 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 20
- 239000012141 concentrate Substances 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 235000010265 sodium sulphite Nutrition 0.000 description 4
- -1 stir evenly Substances 0.000 description 4
- PGTVWKLGGCQMBR-FLBATMFCSA-N Ganaxolone Chemical compound C([C@@H]1CC2)[C@](C)(O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 PGTVWKLGGCQMBR-FLBATMFCSA-N 0.000 description 3
- 229950006567 ganaxolone Drugs 0.000 description 3
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 244000198134 Agave sisalana Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 238000006809 Jones oxidation reaction Methods 0.000 description 1
- XYYYTUCWSSREHK-UHFFFAOYSA-N N1=CC=CC=C1.[N]=O Chemical compound N1=CC=CC=C1.[N]=O XYYYTUCWSSREHK-UHFFFAOYSA-N 0.000 description 1
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 description 1
- 229960000249 pregnenolone Drugs 0.000 description 1
- 150000003146 progesterones Chemical class 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/20—Carbon compounds
- B01J27/232—Carbonates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/006—Catalysts comprising hydrides, coordination complexes or organic compounds comprising organic radicals, e.g. TEMPO
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
- B01J31/0235—Nitrogen containing compounds
- B01J31/0239—Quaternary ammonium compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/70—Oxidation reactions, e.g. epoxidation, (di)hydroxylation, dehydrogenation and analogues
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种5α‑孕甾‑3,20‑二酮的制备方法,它是以妊娠烯醇酮为起始原料,先经催化氢化反应得到3β‑羟基‑5α‑孕甾‑20‑酮,再经催化氧化反应得到5α‑孕甾‑3,20‑二酮;催化氧化是以2,2,6,6‑四甲基哌啶氮氧化物为催化剂、N‑氯代琥珀酰亚胺或者N‑溴代琥珀酰亚胺为氧化剂、四丁基溴化铵为相转移催化剂。本发明的方法以妊娠烯醇酮为起始原料,经两步反应得到5α‑孕甾‑3,20‑二酮,不仅合成路线较短,而且原料来源广泛,适合工业化大生产,本发明的催化氧化体系不仅对环境更友好,而且反应收率和产物纯度均较高。The invention discloses a preparation method of 5α-pregna-3,20-dione, which uses gestational enolone as a starting material, and first undergoes a catalytic hydrogenation reaction to obtain 3β-hydroxy-5α-pregna-20-dione ketone, and then obtain 5α-pregna-3,20-diketone through catalytic oxidation reaction; catalytic oxidation is based on 2,2,6,6-tetramethylpiperidine nitrogen oxide as catalyst, N-chlorosuccinyl Amine or N-bromosuccinimide as oxidant, tetrabutylammonium bromide as phase transfer catalyst. The method of the present invention uses gestational enolone as a starting raw material, and obtains 5α-pregna-3,20-dione through two-step reactions, which not only has a short synthetic route, but also has a wide range of raw material sources, and is suitable for large-scale industrial production. The catalytic oxidation system is not only more friendly to the environment, but also has higher reaction yield and product purity.
Description
技术领域technical field
本发明属于甾体激素药物中间体制备技术领域,具体涉及一种5α-孕甾-3,20-二酮的制备方法。The invention belongs to the technical field of preparation of steroid hormone drug intermediates, and in particular relates to a preparation method of 5α-pregna-3,20-dione.
背景技术Background technique
5α-孕甾-3,20-二酮(也称氢化黄体酮),CAS号为566-65-4,分子式为C21H32O2,分子量为316.48,熔点为200℃,是治疗癫痫病药物加萘索酮的关键中间体。5α-pregna-3,20-dione (also known as hydrogenated progesterone), CAS No. 566-65-4, molecular formula C 21 H 32 O 2 , molecular weight 316.48, melting point 200°C, is used to treat epilepsy The key intermediate of the drug ganaxolone.
文献1公开了一种加那索酮的合成方法,并具体公开了以剑麻皂苷元所得的单烯醇酮醋酸酯【也即3β-羟基-5α-孕甾-16-烯-20-酮醋酸酯,化合物1】为起始原料,先经催化氢化得到3β-羟基-5α-孕甾-20-酮醋酸酯【化合物2】,再经碱性醇解得到3β-羟基-5α-孕甾-20-酮【化合物3】,最后经Jones氧化得到5α-孕甾-3,20-二酮【化合物4】。Document 1 discloses a synthesis method of ganaxolone, and specifically discloses monoenolone acetate obtained from sisal sapogenin [that is, 3β-hydroxyl-5α-pregn-16-en-20-one Acetate, compound 1] as the starting material, 3β-hydroxy-5α-pregna-20-one acetate [compound 2] was obtained by catalytic hydrogenation, and then 3β-hydroxy-5α-pregna was obtained by alkaline alcoholysis -20-ketone [compound 3], and finally oxidized by Jones to obtain 5α-pregna-3,20-dione [compound 4].
该方法的不足在于:(1)合成路线较长;(2)起始原料单烯醇酮醋酸酯来源有限,不易得到;(3)Jones氧化反应会造成大量含铬废水,对环境污染较大,不适合工业化大生产。The disadvantages of this method are: (1) The synthetic route is long; (2) The source of monoenolone acetate as a starting material is limited and difficult to obtain; (3) The Jones oxidation reaction will cause a large amount of chromium-containing wastewater, which will cause great environmental pollution. , not suitable for industrialized mass production.
文献1:何明华等,“加那索酮的合成”,《中国新药杂志》2005年第14卷第8期,第1025-1026页。Document 1: He Minghua et al., "Synthesis of Ganaxolone", "Chinese Journal of New Drugs", Vol. 14, No. 8, 2005, pp. 1025-1026.
发明内容Contents of the invention
本发明的目的在于解决上述问题,提供一种合成路线较短、原料易得、对环境污染较小、反应收率和产物纯度较高的5α-孕甾-3,20-二酮的制备方法。The purpose of the present invention is to solve the above problems and provide a method for preparing 5α-pregna-3,20-dione with short synthetic route, easy to obtain raw materials, less environmental pollution, high reaction yield and product purity .
实现本发明目的的技术方案是:一种5α-孕甾-3,20-二酮的制备方法,其特征在于:以妊娠烯醇酮【也称3β-羟基-孕甾-5-烯-20-酮或者孕烯醇酮】为起始原料,先经催化氢化反应得到3β-羟基-5α-孕甾-20-酮,再经催化氧化反应得到5α-孕甾-3,20-二酮;所述催化氧化是以2,2,6,6-四甲基哌啶氮氧化物(TEMPO)为催化剂、N-氯代琥珀酰亚胺(NCS)或者N-溴代琥珀酰亚胺(NBS)为氧化剂、四丁基溴化铵(TBAB)为相转移催化剂。The technical solution for realizing the purpose of the present invention is: a preparation method of 5α-pregna-3,20-dione, characterized in that: the preparation method of gestational enolone [also known as 3β-hydroxy-pregnant-5-ene-20 -ketone or pregnenolone] as the starting material, first obtain 3β-hydroxyl-5α-pregna-20-one through catalytic hydrogenation reaction, and then obtain 5α-pregna-3,20-dione through catalytic oxidation reaction; The catalytic oxidation uses 2,2,6,6-tetramethylpiperidine nitrogen oxide (TEMPO) as a catalyst, N-chlorosuccinimide (NCS) or N-bromosuccinimide (NBS ) as the oxidant and tetrabutylammonium bromide (TBAB) as the phase transfer catalyst.
合成路线如下:The synthetic route is as follows:
。 .
所述催化氢化反应是在有机溶剂的存在下进行的;所述有机溶剂优选为醇类溶剂;更优选为乙醇;所述妊娠烯醇酮与所述有机溶剂的重量比为1∶40~1∶60。The catalytic hydrogenation reaction is carried out in the presence of an organic solvent; the organic solvent is preferably an alcohol solvent; more preferably ethanol; the weight ratio of the pregnant enolone to the organic solvent is 1:40-1 : 60.
所述催化氢化反应采用的催化体系为钯/碳酸钙催化剂;所述钯/碳酸钙催化剂的用量为所述妊娠烯醇酮重量的10%~50%。The catalytic system used in the catalytic hydrogenation reaction is a palladium/calcium carbonate catalyst; the amount of the palladium/calcium carbonate catalyst is 10% to 50% of the weight of the pregnant enolone.
所述催化氢化反应的温度为20~40℃,压力为0.02~0.06MPa。The temperature of the catalytic hydrogenation reaction is 20-40° C., and the pressure is 0.02-0.06 MPa.
所述催化氧化反应的温度为20~35℃。The temperature of the catalytic oxidation reaction is 20-35°C.
所述2,2,6,6-四甲基哌啶氮氧化物的用量为所述3β-羟基-5α-孕甾-20-酮重量的0.2%~0.6%。The dosage of the 2,2,6,6-tetramethylpiperidine nitrogen oxide is 0.2%-0.6% of the weight of the 3β-hydroxy-5α-pregna-20-one.
所述四丁基溴化铵的用量为所述3β-羟基-5α-孕甾-20-酮重量的10%~20%。The dosage of the tetrabutylammonium bromide is 10%-20% of the weight of the 3β-hydroxy-5α-pregna-20-one.
所述3β-羟基-5α-孕甾-20-酮与所述N-氯代琥珀酰亚胺或者所述N-溴代琥珀酰亚胺的重量比为1∶0.5~1∶1。The weight ratio of the 3β-hydroxy-5α-pregna-20-one to the N-chlorosuccinimide or the N-bromosuccinimide is 1:0.5˜1:1.
所述氧化剂优选为N-氯代琥珀酰亚胺。The oxidizing agent is preferably N-chlorosuccinimide.
所述催化氧化反应是在碳酸钾的存在下进行的;所述3β-羟基-5α-孕甾-20-酮与所述碳酸钾的重量比为1∶0.3~1∶0.6。The catalytic oxidation reaction is carried out in the presence of potassium carbonate; the weight ratio of the 3β-hydroxyl-5α-pregna-20-one to the potassium carbonate is 1:0.3˜1:0.6.
所述催化氧化反应是在有机溶剂的存在下进行的;所述有机溶剂为二氯甲烷、二氯乙烷、三氯甲烷中的一种;所述3β-羟基-5α-孕甾-20-酮与所述有机溶剂的重量比为1∶13~1∶20。The catalytic oxidation reaction is carried out in the presence of an organic solvent; the organic solvent is one of dichloromethane, dichloroethane, and chloroform; the 3β-hydroxyl-5α-pregna-20- The weight ratio of the ketone to the organic solvent is 1:13˜1:20.
本发明具有的积极效果:The positive effect that the present invention has:
(1)本发明的方法以妊娠烯醇酮为起始原料,经两步反应得到5α-孕甾-3,20-二酮,不仅合成路线较短,而且原料来源广泛,适合工业化大生产。(1) The method of the present invention uses pregnant enolone as a starting material to obtain 5α-pregna-3,20-dione through two-step reactions, which not only has a short synthesis route, but also has a wide range of raw material sources, and is suitable for large-scale industrial production.
(2)本发明的方法采用2,2,6,6-四甲基哌啶氮氧化物为催化剂、N-氯代琥珀酰亚胺或者N-氯代琥珀酰亚胺为氧化剂、四正丁基溴化铵为相转移催化剂,在碱性条件下催化氧化3β-羟基-5α-孕甾-20-酮制备5α-孕甾-3,20-二酮,该催化氧化反应不仅对环境更友好,而且反应收率和产物纯度均较高。(2) The method of the present invention uses 2,2,6,6-tetramethylpiperidine nitrogen oxide as a catalyst, N-chlorosuccinimide or N-chlorosuccinimide as an oxidant, tetra-n-butyl Ammonium bromide is used as a phase transfer catalyst to catalyze the oxidation of 3β-hydroxy-5α-pregna-20-one to prepare 5α-pregna-3,20-dione under alkaline conditions. The catalytic oxidation reaction is not only more environmentally friendly , and the reaction yield and product purity are high.
(3)本发明的方法采用钯/碳酸钙催化体系,从而保证得到3β-羟基-5α-孕甾-20-酮。(3) The method of the present invention adopts a palladium/calcium carbonate catalytic system, so as to ensure that 3β-hydroxy-5α-pregna-20-one is obtained.
具体实施方式Detailed ways
(实施例1)(Example 1)
本实施例为妊娠烯醇酮催化氢化制备3β-羟基-5α-孕甾-20-酮,具体方法如下:This example prepares 3β-hydroxy-5α-pregna-20-one by catalytic hydrogenation of pregnant enolone, the specific method is as follows:
将24.00kg的妊娠烯醇酮加入到1200kg的乙醇中,然后加入3.60kg的钯/碳酸钙催化剂,抽真空,用氢气置换3次后,通入氢气,在30℃以及0.04MPa下保温保压反应至完全。Add 24.00kg of pregnant enolone to 1200kg of ethanol, then add 3.60kg of palladium/calcium carbonate catalyst, vacuumize, replace with hydrogen for 3 times, then pass in hydrogen, keep the temperature and pressure at 30°C and 0.04MPa React to complete.
反应结束后,用氮气置换,过滤,洗涤,合并,浓缩滤液除去乙醇,降温至10℃析晶,离心,70~80℃烘干,得到3β-羟基-5α-孕甾-20-酮23.52kg,重量收率为98.0%。After the reaction, replace with nitrogen, filter, wash, combine, concentrate the filtrate to remove ethanol, cool down to 10°C for crystallization, centrifuge, and dry at 70-80°C to obtain 23.52kg of 3β-hydroxy-5α-pregna-20-one , The weight yield is 98.0%.
(实施例2)(Example 2)
本实施例为3β-羟基-5α-孕甾-20-酮催化氧化制备5α-孕甾-3,20-二酮,具体方法如下:This example prepares 5α-pregna-3,20-dione by catalytic oxidation of 3β-hydroxy-5α-pregna-20-one. The specific method is as follows:
将20.00kg实施例1得到的3β-羟基-5α-孕甾-20-酮加入到260kg的二氯甲烷中,搅拌溶解后,先加入0.04kg的2,2,6,6-四甲基哌啶氮氧化物,然后加入由8.00kg的碳酸钾、2.20kg的四丁基溴化铵以及120kg水配制成的溶液,最后再加入10.00kg的N-氯代琥珀酰亚胺,加完,在22℃下保温反应至完全。20.00kg of 3β-hydroxy-5α-pregna-20-one obtained in Example 1 was added to 260kg of dichloromethane, and after stirring and dissolving, 0.04kg of 2,2,6,6-tetramethylpiperene was first added Pyridine nitrogen oxide, then add the solution that is prepared by 8.00kg of potassium carbonate, 2.20kg of tetrabutylammonium bromide and 120kg of water, and finally add 10.00kg of N-chlorosuccinimide. Insulate the reaction at 22°C until complete.
反应结束后,加入由5.00kg的亚硫酸钠和 25.00kg水配制成的溶液,搅拌均匀,50℃浓缩至无二氯甲烷,降温至5℃析晶,离心,水洗,80~90℃烘干,得到5α-孕甾-3,20-二酮粗品19.80kg。After the reaction, add a solution prepared by 5.00kg of sodium sulfite and 25.00kg of water, stir evenly, concentrate at 50°C until there is no dichloromethane, cool down to 5°C for crystallization, centrifuge, wash with water, and dry at 80-90°C to obtain The crude product of 5α-pregna-3,20-dione was 19.80kg.
将上述粗品19.80kg加入到150kg的二氯甲烷中,然后加入2.00kg的活性炭,搅拌脱色50min,过滤,洗涤,合并,浓缩滤液至析出结晶,加入乙酸乙酯,浓缩至无二氯甲烷,降温至5℃析晶,离心过滤,洗涤,70~80℃烘干,得到5α-孕甾-3,20-二酮成品18.80kg,纯度为99.3%,重量收率为94.0%。Add 19.80 kg of the above crude product to 150 kg of dichloromethane, then add 2.00 kg of activated carbon, stir and decolorize for 50 minutes, filter, wash, combine, concentrate the filtrate until crystals are precipitated, add ethyl acetate, concentrate to no dichloromethane, and cool down Crystallize at 5°C, centrifuge filter, wash, and dry at 70-80°C to obtain 18.80 kg of finished product 5α-pregna-3,20-dione with a purity of 99.3% and a weight yield of 94.0%.
(对比例1)(comparative example 1)
本对比例与实施例2的区别在于:没有加入相转移催化剂四丁基溴化铵,结果无目标产物生成。The difference between this comparative example and Example 2 is that no phase transfer catalyst tetrabutylammonium bromide is added, and no target product is generated as a result.
(对比例2~对比例3)(Comparative example 2 to comparative example 3)
各对比例的制备方法与实施例2基本相同,不同之处见表1。The preparation method of each comparative example is basically the same as that of Example 2, and the differences are shown in Table 1.
表1Table 1
(实施例3)(Example 3)
本实施例仍然为妊娠烯醇酮催化氢化制备3β-羟基-5α-孕甾-20-酮,具体方法如下:This example still prepares 3β-hydroxy-5α-pregna-20-one by catalytic hydrogenation of pregnant enolone, the specific method is as follows:
将10.00g的妊娠烯醇酮加入到600g的乙醇中,然后加入3.00g的钯/碳酸钙催化剂,抽真空,用氢气置换3次后,通入氢气,在25℃以及0.05MPa下保温保压反应至完全。Add 10.00g of pregnant enolone to 600g of ethanol, then add 3.00g of palladium/calcium carbonate catalyst, vacuumize, replace with hydrogen for 3 times, then pass in hydrogen, keep the temperature and pressure at 25°C and 0.05MPa React to complete.
反应结束后,用氮气置换,过滤,洗涤,合并,浓缩滤液除去乙醇,降温至10℃析晶,过滤,70~80℃烘干,得到3β-羟基-5α-孕甾-20-酮9.80g,重量收率为98.0%。After the reaction, replace with nitrogen, filter, wash, combine, concentrate the filtrate to remove ethanol, cool down to 10°C to crystallize, filter, and dry at 70-80°C to obtain 9.80 g of 3β-hydroxy-5α-pregna-20-one , The weight yield is 98.0%.
(实施例4)(Example 4)
本实施例仍然为妊娠烯醇酮催化氢化制备3β-羟基-5α-孕甾-20-酮,具体方法如下:This example still prepares 3β-hydroxy-5α-pregna-20-one by catalytic hydrogenation of pregnant enolone, the specific method is as follows:
将10.00g的妊娠烯醇酮加入到500g的乙醇中,然后加入2.00g的钯/碳酸钙催化剂,抽真空,用氢气置换3次后,通入氢气,在30℃以及0.04MPa下保温保压反应至完全。Add 10.00g of pregnant enolone to 500g of ethanol, then add 2.00g of palladium/calcium carbonate catalyst, vacuumize, replace with hydrogen for 3 times, then pass in hydrogen, keep the temperature and pressure at 30°C and 0.04MPa React to complete.
反应结束后,用氮气置换,过滤,洗涤,合并,浓缩滤液除去乙醇,降温至5℃析晶,过滤,70~80℃烘干,得到3β-羟基-5α-孕甾-20-酮9.76g,重量收率为97.6%。After the reaction, replace with nitrogen, filter, wash, combine, concentrate the filtrate to remove ethanol, cool down to 5°C to crystallize, filter, and dry at 70-80°C to obtain 9.76g of 3β-hydroxy-5α-pregna-20-one , The weight yield is 97.6%.
(实施例5)(Example 5)
本实施例仍然为妊娠烯醇酮催化氢化制备3β-羟基-5α-孕甾-20-酮,具体方法如下:This example still prepares 3β-hydroxy-5α-pregna-20-one by catalytic hydrogenation of pregnant enolone, the specific method is as follows:
将10.00g的妊娠烯醇酮加入到400g的乙醇中,然后加入1.00g的钯/碳酸钙催化剂,抽真空,用氢气置换3次后,通入氢气,在35℃以及0.03MPa下保温保压反应至完全。Add 10.00g of pregnant enolone to 400g of ethanol, then add 1.00g of palladium/calcium carbonate catalyst, vacuumize, replace with hydrogen for 3 times, then pass in hydrogen, keep the temperature and pressure at 35°C and 0.03MPa React to complete.
反应结束后,用氮气置换,过滤,洗涤,合并,浓缩滤液除去乙醇,降温至10℃析晶,过滤,70~80℃烘干,得到3β-羟基-5α-孕甾-20-酮9.70g,重量收率为97.0%。After the reaction, replace with nitrogen, filter, wash, combine, concentrate the filtrate to remove ethanol, cool down to 10°C for crystallization, filter, and dry at 70-80°C to obtain 9.70 g of 3β-hydroxy-5α-pregna-20-one , The weight yield is 97.0%.
(实施例6)(Example 6)
本实施例仍然为3β-羟基-5α-孕甾-20-酮催化氧化制备5α-孕甾-3,20-二酮,具体方法如下:This example still prepares 5α-pregna-3,20-dione by catalytic oxidation of 3β-hydroxy-5α-pregna-20-one, the specific method is as follows:
将10.00g的3β-羟基-5α-孕甾-20-酮加入到150g的二氯甲烷中,搅拌溶解后,先加入0.03g 的2,2,6,6-四甲基哌啶氮氧化物,然后加入由5.00g的碳酸钾、1.50g的四丁基溴化铵以及60g水配制成的溶液,最后加入10.00g 的N-氯代琥珀酰亚胺,加完,在30℃下保温反应至完全。Add 10.00g of 3β-hydroxy-5α-pregna-20-one into 150g of dichloromethane, stir and dissolve, then add 0.03g of 2,2,6,6-tetramethylpiperidine nitrogen oxide , then add a solution prepared by 5.00g of potassium carbonate, 1.50g of tetrabutylammonium bromide and 60g of water, and finally add 10.00g of N-chlorosuccinimide, after the addition is complete, keep the temperature at 30°C for reaction to complete.
反应结束后,加入由2.50g的亚硫酸钠和 12.50g水配制成的溶液,搅拌均匀,50℃浓缩至无二氯甲烷,降温至15℃析晶,过滤,水洗,80~90℃烘干,得到5α-孕甾-3,20-二酮粗品9.80g。After the reaction, add a solution prepared by 2.50g of sodium sulfite and 12.50g of water, stir evenly, concentrate at 50°C until there is no dichloromethane, cool down to 15°C to crystallize, filter, wash with water, and dry at 80-90°C to obtain 9.80 g of the crude product of 5α-pregna-3,20-dione.
将上述粗品9.80g加入到100g的二氯甲烷中,然后加入1.00g的活性炭,搅拌脱色50min,过滤,洗涤,合并,浓缩滤液至析出结晶,加入乙酸乙酯,浓缩至无二氯甲烷,降温至10℃析晶,过滤,洗涤,70~80℃烘干,得到5α-孕甾-3,20-二酮成品9.22g,纯度为99.2%,精制收率为92.2%。Add 9.80 g of the above crude product to 100 g of dichloromethane, then add 1.00 g of activated carbon, stir for decolorization for 50 minutes, filter, wash, combine, concentrate the filtrate until crystals are precipitated, add ethyl acetate, concentrate to no dichloromethane, and cool down Crystallize at 10°C, filter, wash, and dry at 70-80°C to obtain 9.22 g of finished product 5α-pregna-3,20-dione with a purity of 99.2% and a refined yield of 92.2%.
(实施例7)(Example 7)
本实施例仍然为3β-羟基-5α-孕甾-20-酮催化氧化制备5α-孕甾-3,20-二酮,具体方法如下:This example still prepares 5α-pregna-3,20-dione by catalytic oxidation of 3β-hydroxy-5α-pregna-20-one, the specific method is as follows:
将10.00g的3β-羟基-5α-孕甾-20-酮加入到200g的二氯乙烷中,搅拌溶解后,先加入0.06g 的2,2,6,6-四甲基哌啶氮氧化物,然后加入由3.00g的碳酸钾、1.00g的四丁基溴化铵以及60g水配制成的溶液,最后加入6.00g的N-溴代琥珀酰亚胺,加完,在32℃下保温反应至完全。Add 10.00g of 3β-hydroxy-5α-pregna-20-one into 200g of dichloroethane, stir and dissolve, then add 0.06g of 2,2,6,6-tetramethylpiperidine for nitrogen oxidation Then add a solution prepared by 3.00g of potassium carbonate, 1.00g of tetrabutylammonium bromide and 60g of water, and finally add 6.00g of N-bromosuccinimide, after adding, keep warm at 32°C React to complete.
反应结束后,加入由2.50g的亚硫酸钠和12.50g水配制成的溶液,搅拌均匀,50℃浓缩至无二氯乙烷,降温至10℃析晶,过滤,水洗,80~90℃烘干,得到5α-孕甾-3,20-二酮粗品9.70g。After the reaction, add a solution prepared by 2.50g of sodium sulfite and 12.50g of water, stir evenly, concentrate at 50°C until there is no dichloroethane, cool down to 10°C to crystallize, filter, wash with water, and dry at 80-90°C. 9.70 g of crude 5α-pregna-3,20-dione was obtained.
将上述粗品9.70g加入到50g的二氯甲烷中,然后加入0.50g的活性炭,搅拌脱色45min,过滤,洗涤,合并,浓缩滤液至析出结晶,加入乙酸乙酯,浓缩至无二氯甲烷,降温至5℃析晶,过滤,洗涤,70~80℃烘干,得到5α-孕甾-3,20-二酮成品8.94g,纯度为99.1%,精制收率为89.4%。Add 9.70 g of the above crude product to 50 g of dichloromethane, then add 0.50 g of activated carbon, stir for decolorization for 45 minutes, filter, wash, combine, concentrate the filtrate until crystals are precipitated, add ethyl acetate, concentrate to no dichloromethane, and cool down Crystallize at 5°C, filter, wash, and dry at 70-80°C to obtain 8.94g of 5α-pregna-3,20-dione finished product with a purity of 99.1% and a refined yield of 89.4%.
(实施例8)(Example 8)
本实施例仍然为3β-羟基-5α-孕甾-20-酮催化氧化制备5α-孕甾-3,20-二酮,具体方法如下:This example still prepares 5α-pregna-3,20-dione by catalytic oxidation of 3β-hydroxy-5α-pregna-20-one, the specific method is as follows:
将10.00g的3β-羟基-5α-孕甾-20-酮加入到130g的二氯甲烷中,搅拌溶解后,先加入0.03g 的2,2,6,6-四甲基哌啶氮氧化物,然后加入由3.00g的碳酸钾、1.50g的四丁基溴化铵以及60g水配制成的溶液,最后加入5.00g 的N-氯代琥珀酰亚胺,加完,在20℃下保温反应至完全。Add 10.00g of 3β-hydroxy-5α-pregna-20-one into 130g of dichloromethane, stir and dissolve, then add 0.03g of 2,2,6,6-tetramethylpiperidine nitrogen oxide , then add a solution prepared by 3.00g of potassium carbonate, 1.50g of tetrabutylammonium bromide and 60g of water, and finally add 5.00g of N-chlorosuccinimide, after the addition is complete, keep the temperature at 20°C for reaction to complete.
反应结束后,加入由2.50g的亚硫酸钠和12.50g水配制成的溶液,搅拌均匀,50℃浓缩至无二氯甲烷,降温至5℃析晶,过滤,水洗,80~90℃烘干,得到5α-孕甾-3,20-二酮粗品9.85g。After the reaction, add a solution prepared by 2.50g of sodium sulfite and 12.50g of water, stir evenly, concentrate at 50°C until there is no dichloromethane, cool down to 5°C for crystallization, filter, wash with water, and dry at 80-90°C to obtain 9.85 g of the crude product of 5α-pregna-3,20-dione.
将上述粗品9.85g加入到80g的二氯甲烷中,然后加入1.00g的活性炭,搅拌脱色50min,过滤,洗涤,合并,浓缩滤液至析出结晶,加入乙酸乙酯,浓缩至无二氯甲烷,降温至5℃析晶,过滤,洗涤,70~80℃烘干,得到5α-孕甾-3,20-二酮成品9.32g,纯度为99.4%,重量收率为93.2%。Add 9.85 g of the above crude product to 80 g of dichloromethane, then add 1.00 g of activated carbon, stir for 50 minutes to decolorize, filter, wash, combine, concentrate the filtrate until crystals are precipitated, add ethyl acetate, concentrate to no dichloromethane, and cool down Crystallize at 5°C, filter, wash, and dry at 70-80°C to obtain 9.32 g of finished product 5α-pregna-3,20-dione with a purity of 99.4% and a weight yield of 93.2%.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211577135.5A CN116143859A (en) | 2022-12-09 | 2022-12-09 | Preparation method of 5α-pregna-3,20-dione |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211577135.5A CN116143859A (en) | 2022-12-09 | 2022-12-09 | Preparation method of 5α-pregna-3,20-dione |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116143859A true CN116143859A (en) | 2023-05-23 |
Family
ID=86360930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211577135.5A Pending CN116143859A (en) | 2022-12-09 | 2022-12-09 | Preparation method of 5α-pregna-3,20-dione |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116143859A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110306579A1 (en) * | 2009-01-30 | 2011-12-15 | Emory University | Methods of neuroprotection using neuroprotective steroids and a vitamin d |
CN110698322A (en) * | 2019-10-15 | 2020-01-17 | 浙江大学 | A kind of synthetic method of coastal twin anthoane diterpene Stemarin |
CN112501235A (en) * | 2020-11-19 | 2021-03-16 | 华东师范大学 | Method for preparing breynolone by using monoalcohol ketone acetate |
CN115181153A (en) * | 2016-10-18 | 2022-10-14 | 萨奇治疗股份有限公司 | Oxysterol and methods of use thereof |
-
2022
- 2022-12-09 CN CN202211577135.5A patent/CN116143859A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110306579A1 (en) * | 2009-01-30 | 2011-12-15 | Emory University | Methods of neuroprotection using neuroprotective steroids and a vitamin d |
CN115181153A (en) * | 2016-10-18 | 2022-10-14 | 萨奇治疗股份有限公司 | Oxysterol and methods of use thereof |
CN110698322A (en) * | 2019-10-15 | 2020-01-17 | 浙江大学 | A kind of synthetic method of coastal twin anthoane diterpene Stemarin |
CN112501235A (en) * | 2020-11-19 | 2021-03-16 | 华东师范大学 | Method for preparing breynolone by using monoalcohol ketone acetate |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104496738A (en) | Method for preparing sulfonamide and derivatives thereof | |
PT2004669E (en) | Azaheterocyclyl derivatives of androstanes and androstenes as medicaments for cardiovascular disorders | |
PT2004668E (en) | Amino derivatives of androstanes and androstenes as medicaments for cardiovascular disorders | |
CN102558017A (en) | Method for preparing 5-bromoindole | |
CN101302244B (en) | Production process of betulinic acid | |
CN116143859A (en) | Preparation method of 5α-pregna-3,20-dione | |
CN104945341B (en) | A kind of method of the triazole compound of three components one pot process 1,2,3 | |
CN101845075B (en) | 6-substituted-4-azepine-A-homo-3-oxosteroid compound and application thereof to preparing anti-tumor medicine | |
CN101323636A (en) | A kind of method for preparing rocuronium bromide | |
CN107501373A (en) | A kind of preparation method of danabol | |
CN108070013A (en) | The preparation method of 21- halogenated steroid compounds | |
CN108084078A (en) | A kind of synthetic method for the drug Apremilast for treating psoriasis arthropathica disease | |
CN106278928B (en) | A kind of synthetic method of Oseltamivir phosphate isomer impurities | |
CN104119414A (en) | Preparation method of high-quality progesterone | |
CN107936061A (en) | A kind of synthetic method of endoxan | |
CN116041410A (en) | Preparation method of 4-pregnene-3, 11, 20-trione | |
CN114539098A (en) | A kind of bifunctional HDAC6 inhibitor, synthesis method and application | |
CN106188202B (en) | The synthesis testosterone method that the glycol content of by-product 3,17 is greatly reduced | |
US2786837A (en) | Compounds for synthesizing steroids | |
CN114075110B (en) | Modification method of pleuromutilin and application of pleuromutilin in preparation of tiamulin | |
CN114181330B (en) | A preparation method of sugammadex sodium intermediate | |
CN103254268A (en) | Process for preparing dutasteride | |
CN117510392A (en) | Preparation method of bisindolyl compound | |
CN117946199A (en) | Preparation method of drospirenone key intermediate | |
CN109942659B (en) | Synthetic method of betamethasone intermediate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |